Clinical Trials Directory

Trials / Completed

CompletedNCT02615665

Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases

Role of CD3+ and NKp46+ Cells in Resected Colorectal Liver Metastases.

Status
Completed
Phase
Study type
Observational
Enrollment
121 (actual)
Sponsor
University of Milan · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The long-term outcome of patients resected for colorectal liver metastases (CLM) after neoadjuvant chemotherapy (CHT) depends by several tumoral and non-tumoral factors, such as the immune response to the tumor and to the CHT. The aim of this study was to investigate the impact of the pathological and immunological response in patients undergoing liver resection for CLM after CHT in regards to the long-term outcome.

Detailed description

The immunoreactivity to CD3+ and NKp46+ cells inside the tumor, at the border between the tumor and the normal liver, and inside the normal liver will be tested by computer-assisted image analyses in patients undergoing liver resection for CLM between 2005 and 2013 preoperatively treated with oxaliplatin or irinotecan with or without bevacizumab or cetuximab. The survival will be assessed in relation to several prognostic factors and to that immunoreactivity.

Conditions

Interventions

TypeNameDescription
PROCEDUREHepatic resectionRemoval of a part of the liver during surgery

Timeline

Start date
2013-01-01
Primary completion
2015-08-01
Completion
2015-08-01
First posted
2015-11-26
Last updated
2015-11-26

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT02615665. Inclusion in this directory is not an endorsement.

Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases (NCT02615665) · Clinical Trials Directory